Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial

Jackson, Daniel J.; Bacharier, Leonard B.; Gergen, Peter J.; Gagalis, Lisa; Calatroni, Agustin; Wellford, Stephanie; Gill, Michelle A.; Stokes, Jeffrey R.; Liu, Andrew H.; Gruchalla, Rebecca S.; Cohen, Robyn T.; Makhija, Melanie; Hershey, Gurjit K. Khurana; O’Connor, George T.; Pongracic, Jacqueline A.; Sherenian, Michael G.; Rivera-Spoljaric, Katherine; Zoratti, Edward M.; Teach, Stephen J.; Kattan, Meyer; Dutmer, Cullen M.; Kim, Hae Jin; Lamm, Carin; Sheehan, William J.; Segnitz, R. Max; Dill‐McFarland, Kimberly A.; Visness, Cynthia M.; Becker, Patrice M.; Gern, James E.; Sorkness, Christine A.; Busse, William W.; Altman, Matthew C.

doi:10.1016/s0140-6736(22)01198-9

Cited by 84 publications

(42 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mepolizumab—a monoclonal antibody against interleukin-5— is an effective and well-tolerated treatment that reduces the risk of asthma exacerbations in patients with severe eosinophilic asthma ( Pavord et al, 2012 ) and also be useful in an emergency to treat steroid-refractory eosinophilic acute severe asthma ( Barbarot et al, 2022 ). Phenotype-directed therapy with mepolizumab in urban children (aged 6–17 years) with exacerbation-prone eosinophilic asthma reduced the number of exacerbations ( Jackson et al, 2022 ). In patients with persistent, moderate-to-severe asthma and elevated eosinophil levels who used inhaled glucocorticoids and LABAs, dupilumab therapy, as compared with placebo, was associated with fewer asthma exacerbations when LABAs and inhaled glucocorticoids were withdrawn, with improved lung function and reduced levels of Th2-associated inflammatory markers ( Wenzel et al, 2013 ).…”

Section: Discussionmentioning

confidence: 99%

A bibliometric and scientific knowledge map study of the drug therapies for asthma-related study from 1982 to 2021

Gao

Yingying

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: Asthma drug research has been increasing yearly, and its clinical application value has increasingly attracted attention. This study aimed to analyze the development status, research hotspots, research frontiers, and future development trends of the research works on drugs for patients with asthma, especially severe asthma.Methods: Asthma drug-related articles published between 1982 and 2021 were retrieved from the Web of Science Core Collection (WOSCC) database, and only articles published in English were included. CiteSpace and VOSviewer software were utilized to conduct collaborative network analysis of countries/regions, institutions, keywords, and co-citation analysis of references.Results: A total of 3,234 asthma drug-related eligible articles were included. The United States was in a leading position, and Karolinska Institute (Sweden) was the most active institution. The most prolific journal in this field was Journal of Asthma, and the most cited journal was Journal of Allergy and Clinical Immunology. Keyword co-occurrence studies suggested that the current hotspots and frontiers were as follows: ① asthma: fully revealing the potential of existing conventional asthma drugs, determining the best drug delivery system, and indicating the best combination. To continue to explore potential targets for severe asthma or other phenotypes. Inhaled glucocorticoids and budesonide are still one of the important aspects of current asthma drug research and ② severe asthma: the research and development of new drugs, especially monoclonal antibodies including omalizumab, mepolizumab, and benralizumab to improve asthma control and drug safety, have become a research hotspot in recent years, highlighting the importance of “target” selection.Conclusion: This study demonstrates the global research hotspots and trends of the research works on drugs for patients with asthma/severe asthma. It can help scholars quickly understand the current status and hotspots of research in this field.

show abstract

Section: Discussionmentioning

confidence: 99%

A bibliometric and scientific knowledge map study of the drug therapies for asthma-related study from 1982 to 2021

Gao

Yingying

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Mepolizumab reduced asthma exacerbation rates compared with placebo in this population (1.0 versus 1.3 per year, relative risk 0.73), but the improvement was less than that observed in prior trials of adults and adolescents (relative risk approximately 0.50). 1 Whether this lesser performance is due to ongoing environmental exposure, higher levels of noneosinophilic infl ammation, biologic changes between childhood and adult asthma, or other differences in the overall study populations is not well understood.…”

Section: Allergy and Immunology -Asthma And Copdmentioning

confidence: 99%

UpToDate®

2023

The Nurse Practitioner

View full text Add to dashboard Cite

Disclaimer: This content is provided for reference purposes only and represents a portion of the UpToDate topic. Readers should not rely on the content or any information cited here as being applicable to specifi c patient circumstances. All topics are updated as new evidence becomes available and our peer review process is complete.UpToDate ® and The Nurse Practitioner are collaborating to present select "What's New" content. UpToDate is an evidence-based, clinical support resource used worldwide by healthcare practitioners to make decisions at the point of care. For complete, current "What's New" content, or to become a subscriber for full content access, visit go.uptodate.com/np. "What's New" is free for all medical professionals.

show abstract

“…Clinical trials involving mepolizumab include DREAM [30], MENSA [31], SIRIUS [32], MUSCA [33], and MUPPITS-2 [34 ▪ ]. In MENSA and MUSCA, participants with severe eosinophilic asthma were randomized to receive mepolizumab (given intravenously or subcutaneously) or placebo for 32 weeks (MENSA) or 24 weeks (MUSCA).…”

Section: Biologic Agents For Pediatric Severe Asthmamentioning

confidence: 99%

Biologics and severe asthma in children

Saxena

Rosas‐Salazar

Fitzpatrick

et al. 2022

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Purpose of reviewSevere asthma can carry significant morbidity and mortality for patients, and it places a burden on families and the healthcare system. Biologic agents have revolutionized the care of patients with severe asthma in recent years. Evidence surrounding some of these therapies is limited in the pediatric population, but recent studies show that they significantly improve asthma care when used appropriately. In this review, we discuss the biologic therapies currently approved to treat severe asthma in school-age children and adolescents. Recent findingsRandomized controlled trials have been published in support of biologics in children and/or adolescents. These therapies have been shown to reduce the annual rate of severe asthma exacerbations by at least 40--50%, and some up to about 70%. Improvements in asthma control, lung function, oral corticosteroid use, and quality of life have also been demonstrated, although these vary by agent. Furthermore, these therapies have reassuring safety profiles in pediatric patients.

show abstract

Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial

Cited by 84 publications

References 34 publications

A bibliometric and scientific knowledge map study of the drug therapies for asthma-related study from 1982 to 2021

A bibliometric and scientific knowledge map study of the drug therapies for asthma-related study from 1982 to 2021

UpToDate®

Biologics and severe asthma in children

Contact Info

Product

Resources

About